Literature DB >> 21464431

Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia.

M Elamin1, J Phukan, P Bede, N Jordan, S Byrne, N Pender, O Hardiman.   

Abstract

BACKGROUND: The prognostic implications of cognitive impairment in amyotrophic lateral sclerosis (ALS) are not established.
OBJECTIVES: To investigate the survival effect of the comorbid frontotemporal dementia (FTD) and to determine whether, in the absence of dementia, impairment in different cognitive domains affects outcome.
METHODS: A prospective population-based study of incident cases of ALS in the Republic of Ireland included home-based neuropsychological assessments using age-, sex-, and education-matched controls. Four cognitive domains were evaluated: executive function, memory, language, and visuospatial skills.
RESULTS: Mean age of the participants (n = 139) was 63.3 years; 61.2% were male and 35.3% had bulbar-onset ALS. Factors associated with shorter survival included age more than 60, severe disability at baseline, shorter delay to diagnosis, and early respiratory involvement. Comorbid FTD was associated with significantly shorter survival time (hazard ratio [HR] 2.67, 95% confidence interval [CI] 1.04-6.85, p = 0.041). In patients with ALS without dementia, the presence of executive dysfunction was significantly associated with shorter survival. This was confirmed in a multivariate model that included age, delay to diagnosis, disease severity at baseline, education, and respiratory status (HR 3.44, 95% CI 1.45-8.18, p = 0.005). In the absence of executive dysfunction, single or multi-domain impairment in other cognitive domains had no significant effect on survival.
CONCLUSION: Comorbid frontotemporal dementia is a negative prognostic indicator. In patients with ALS without dementia, executive dysfunction, but not impairment in other cognitive domains, is an important negative prognostic indicator.

Entities:  

Mesh:

Year:  2011        PMID: 21464431     DOI: 10.1212/WNL.0b013e318214359f

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  83 in total

1.  Deficits in concept formation in amyotrophic lateral sclerosis.

Authors:  David J Libon; Corey McMillan; Brian Avants; Ashley Boller; Brianna Morgan; Lisa Burkholder; Keerthi Chandrasekaran; Lauren Elman; Leo McCluskey; Murray Grossman
Journal:  Neuropsychology       Date:  2012-05-21       Impact factor: 3.295

2.  Multiparametric MRI study of ALS stratified for the C9orf72 genotype.

Authors:  Peter Bede; Arun L W Bokde; Susan Byrne; Marwa Elamin; Russell L McLaughlin; Kevin Kenna; Andrew J Fagan; Niall Pender; Daniel G Bradley; Orla Hardiman
Journal:  Neurology       Date:  2013-06-14       Impact factor: 9.910

3.  Caregiver burden in amyotrophic lateral sclerosis: a cross-sectional investigation of predictors.

Authors:  Tom Burke; Marwa Elamin; Miriam Galvin; Orla Hardiman; Niall Pender
Journal:  J Neurol       Date:  2015-04-23       Impact factor: 4.849

4.  Eye-tracking controlled cognitive function tests in patients with amyotrophic lateral sclerosis: a controlled proof-of-principle study.

Authors:  Jürgen Keller; Martin Gorges; Hannah T Horn; Helena E A Aho-Özhan; Elmar H Pinkhardt; Ingo Uttner; Jan Kassubek; Albert C Ludolph; Dorothée Lulé
Journal:  J Neurol       Date:  2015-06-05       Impact factor: 4.849

Review 5.  Challenges in the Understanding and Treatment of Amyotrophic Lateral Sclerosis/Motor Neuron Disease.

Authors:  Jeffrey Rosenfeld; Michael J Strong
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

6.  Extra-motor cerebral changes and manifestations in primary lateral sclerosis.

Authors:  Eoin Finegan; Stacey Li Hi Shing; Rangariroyashe H Chipika; Kai Ming Chang; Mary Clare McKenna; Mark A Doherty; Jennifer C Hengeveld; Alice Vajda; Niall Pender; Colette Donaghy; Siobhan Hutchinson; Russell L McLaughlin; Orla Hardiman; Peter Bede
Journal:  Brain Imaging Behav       Date:  2021-01-07       Impact factor: 3.978

Review 7.  Clinical diagnosis and management of amyotrophic lateral sclerosis.

Authors:  Orla Hardiman; Leonard H van den Berg; Matthew C Kiernan
Journal:  Nat Rev Neurol       Date:  2011-10-11       Impact factor: 42.937

8.  Measuring reliable change in cognition using the Edinburgh Cognitive and Behavioural ALS Screen (ECAS).

Authors:  Christopher Crockford; Judith Newton; Katie Lonergan; Caoifa Madden; Iain Mays; Meabhdh O'Sullivan; Emmet Costello; Marta Pinto-Grau; Alice Vajda; Mark Heverin; Niall Pender; Ammar Al-Chalabi; Orla Hardiman; Sharon Abrahams
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2017-12-07       Impact factor: 4.092

9.  Longitudinal predictors of caregiver burden in amyotrophic lateral sclerosis: a population-based cohort of patient-caregiver dyads.

Authors:  Tom Burke; Orla Hardiman; Marta Pinto-Grau; Katie Lonergan; Mark Heverin; Katy Tobin; Anthony Staines; Miriam Galvin; Niall Pender
Journal:  J Neurol       Date:  2018-02-02       Impact factor: 4.849

Review 10.  Current pathways for epidemiological research in amyotrophic lateral sclerosis.

Authors:  Pam Factor-Litvak; Ammar Al-Chalabi; Alberto Ascherio; Walter Bradley; Adriano Chío; Ralph Garruto; Orla Hardiman; Freya Kamel; Edward Kasarskis; Ann McKee; Imaharu Nakano; Lorene M Nelson; Andrew Eisen
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2013-05       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.